305 related articles for article (PubMed ID: 30626425)
1. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I; Morabito F; Giuliani N; Terragna C; Omedè P; Palumbo A; Bringhen S; De Paoli L; Martino E; Larocca A; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Dammacco F; Boccadoro M; Vacca A; Ria R
J Hematol Oncol; 2019 Jan; 12(1):4. PubMed ID: 30626425
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.
Pour L; Svachova H; Adam Z; Mikulkova Z; Buresova L; Kovarova L; Buchler T; Penka M; Vorlicek J; Hajek R
Neoplasma; 2010; 57(1):29-34. PubMed ID: 19895169
[TBL] [Abstract][Full Text] [Related]
4. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
6. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
7. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.
Pour L; Svachova H; Adam Z; Almasi M; Buresova L; Buchler T; Kovarova L; Nemec P; Penka M; Vorlicek J; Hajek R
Ann Hematol; 2010 Apr; 89(4):385-9. PubMed ID: 19784651
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
[TBL] [Abstract][Full Text] [Related]
11. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
Sato N; Hattori Y; Wenlin D; Yamada T; Kamata T; Kakimoto T; Okamoto S; Kawamura C; Kizaki M; Shimada N; Ote Y; Hata J; Ikeda Y
Jpn J Cancer Res; 2002 Apr; 93(4):459-66. PubMed ID: 11985797
[TBL] [Abstract][Full Text] [Related]
12. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
13. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Inanç M; Er O; Karaca H; Berk V; Ozkan M; Saraymen R; Elmalı F
Med Oncol; 2012 Dec; 29(5):3119-24. PubMed ID: 22580817
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
Kara IO; Sahin B; Gunesacar R; Unsal C
Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
[TBL] [Abstract][Full Text] [Related]
17. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
18. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1347-51. PubMed ID: 12952228
[TBL] [Abstract][Full Text] [Related]
19. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
20. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels.
Iwasaki T; Sano H
Leuk Lymphoma; 2003 Aug; 44(8):1275-9. PubMed ID: 12952219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
